Showing results (3741-3750 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|May 3, 2013
Role of postoperative vitamin D and/or calcium routine supplementation in preventing hypocalcemia after thyroidectomy: a systematic review and meta-analysisAmal Alhefdhi, Haggi Mazeh, Herbert Chen
The Oncologist|July 27, 2014
Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patientsAlberto Farolfi, Corradina Della Luna, Angela Ragazzini, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
The Oncologist|August 3, 2014
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world settingSara Hurvitz, Annie Guerin, Melissa Brammer, et al.
The Oncologist|August 3, 2014
Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancerVeena Shankaran, David Mummy, Lisel Koepl, et al.
The Oncologist|August 14, 2014
The association of hospital spending intensity and cancer outcomes: a population-based study in an Asian countryTing-Shou Chang, Kuang-Yung Huang, Chun-Ming Chang, et al.
The Oncologist|December 6, 2013
Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshopErin P Balogh, Carolyn Dresler, Mark E Fleury, et al.
The Oncologist|January 10, 2013
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims dataApril Teitelbaum, Abbie Ba-Mancini, Hui Huang, et al.
The Oncologist|January 10, 2013
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatmentLouis P Garrison, Si-Tien Wang, Hui Huang, et al.
The Oncologist|December 15, 2012
Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioidsAkhila Reddy, Sriram Yennurajalingam, Kalyan Pulivarthi, et al.
Pageof 571